TNG Transgene SA

Availability of Transgene’s 2025 Universal Registration Document (URD)

Availability of Transgene’s 2025 Universal Registration Document (URD)

Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, announces that the French version of its 2025 Universal Registration Document was filed with the French Financial Markets Authority (Autorité des marchés financiers – AMF) on April 9, 2026, under number D.26-0241.

This document, available on the AMF’s website (), can be viewed and downloaded (in PDF format in French and English, and in ESEF format in French only) on Transgene’s website ().

It includes the following documents:

  • the Annual Financial Report;
  • the Board of Directors’ Corporate Governance Report;
  • the Statutory Auditors’ Reports;
  • information on the Company’s share capital, including the share buyback program;
  • information on the Statutory Auditors’ fees.

The Universal Registration Document also includes information on the Company’s Environmental, Social and Governance (ESG) factors.

Attachment



EN
09/04/2026

Underlying

TNGTransgene SA

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Transgene SA

Jamila El Bougrini ... (+2)
  • Jamila El Bougrini
  • Thibaut Voglimacci-Stephanopoli
04/13/26 April 13, 2026 1 FR
 PRESS RELEASE
Free
TNG TRANSGENE SA

Transgene Completes Patient Randomization in Phase 2 Part of Clinical ...

Transgene Completes Patient Randomization in Phase 2 Part of Clinical Trial Evaluating TG4050 in the Adjuvant Treatment of Head and Neck Cancer Two-year disease-free survival from evaluable Phase 2 patients expected by the end of Q1 2028. Strasbourg, France, April 13, 2026, 8:00 a.m. CET – Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, today announced the completion of patient randomization in the Phase 2 part of the Phase 1/2 clinical trial evaluating TG4050, an individualized neoantigen therapeutic vac...

April 13, 2026 1 EN
 PRESS RELEASE
Free
TNG TRANSGENE SA

Transgene annonce la fin de la randomisation des patients de la partie...

Transgene annonce la fin de la randomisation des patients de la partie Phase 2 de l’essai clinique évaluant TG4050 dans le traitement adjuvant des cancers de la tête et du cou Survie sans récidive (DFS) à deux ans attendue au plus tard à la fin du 1er trimestre 2028 pour les patients évaluables de la partie Phase 2 Strasbourg, France, le 13 avril 2026, 8 h 00 – Transgene (Euronext Paris : TNG), société de biotechnologie qui conçoit et développe des immunothérapies reposant sur des vecteurs viraux contre les cancers, annonce aujourd’hui la fin de la randomisation des patients de la partie...

April 13, 2026 1 EN
 PRESS RELEASE
Free
TNG TRANSGENE SA

Availability of Transgene’s 2025 Universal Registration Document (URD...

Availability of Transgene’s 2025 Universal Registration Document (URD) Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, announces that the French version of its 2025 Universal Registration Document was filed with the French Financial Markets Authority (Autorité des marchés financiers – AMF) on April 9, 2026, under number D.26-0241. This document, available on the AMF’s website (), can be viewed and downloaded (in PDF format in French and English, and in ESEF format in French only) on Transgene’s website (...

April 9, 2026 1 EN
 PRESS RELEASE
Free
TNG TRANSGENE SA

Mise à disposition du Document d’Enregistrement Universel (DEU) 2025 d...

Mise à disposition du Document d’Enregistrement Universel (DEU) 2025 de Transgene Transgene (Euronext Paris : TNG), société de biotechnologie qui conçoit et développe des immunothérapies contre le cancer reposant sur des vecteurs viraux, annonce avoir déposé son Document d’Enregistrement Universel 2025 en français, auprès de l’Autorité des Marchés Financiers (AMF) le 9 avril 2026, sous le numéro D.26-0241. Ce document, disponible sur le site internet de l’Autorité des Marchés Financiers (), peut être consulté et téléchargé (au format PDF en français et en anglais et au format ESEF en franç...

April 9, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch